TD Securities downgraded Valeant Pharmaceuticals (NYSE: VRX) from Buy to Hold with a price target of $110.00 (from $155.00). The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE